Cargando…

Population‐level evidence of survival benefits of patient‐reported outcome symptom monitoring software systems in routine cancer care

Detalles Bibliográficos
Autores principales:	Basch, Ethan, Charlot, Marjory, Dueck, Amylou C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643649/ https://www.ncbi.nlm.nih.gov/pubmed/33029950 http://dx.doi.org/10.1002/cam4.3480

Ejemplares similares

Patient reported symptoms associated with quality of life during chemo‐ or immunotherapy for bladder cancer patients with advanced disease
por: Taarnhøj, Gry A., et al.
Publicado: (2020)

Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition
por: Padrnos, Leslie, et al.
Publicado: (2020)

The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms
por: Gowin, Krisstina, et al.
Publicado: (2020)

The impact of routine Edmonton Symptom Assessment System (ESAS) use on overall survival in cancer patients: Results of a population‐based retrospective matched cohort analysis
por: Barbera, Lisa, et al.
Publicado: (2020)

Quality of life and disease understanding: impact of attending a patient-centered cancer symposium
por: Padrnos, Leslie, et al.
Publicado: (2015)

Employment benefits and job retention: evidence among patients with colorectal cancer
por: Veenstra, Christine M., et al.
Publicado: (2018)

Survival benefit of sphingosin‐1‐phosphate and receptors expressions in breast cancer patients
por: Lei, Fu‐Ju, et al.
Publicado: (2018)

Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy
por: Zhao, Zongxing, et al.
Publicado: (2020)

Symptom clusters and survival in Portuguese patients with advanced cancer
por: Barata, Pedro C., et al.
Publicado: (2016)

Application of a Bayesian graded response model to characterize areas of disagreement between clinician and patient grading of symptomatic adverse events
por: Atkinson, Thomas M., et al.
Publicado: (2018)

Individualized prediction of survival benefits from perioperative chemoradiotherapy for patients with resectable gastric cancer
por: Che, Keying, et al.
Publicado: (2020)

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development
por: Geyer, Holly L., et al.
Publicado: (2015)

Automated home monitoring and management of patient‐reported symptoms during chemotherapy: results of the symptom care at home RCT
por: Mooney, Kathi H., et al.
Publicado: (2017)

Survival benefit of gastrectomy for gastric cancer with peritoneal carcinomatosis: a propensity score‐matched analysis
por: Geng, Xiuwen, et al.
Publicado: (2016)

Radiotherapy after surgery has significant survival benefits for patients with triple‐negative breast cancer
por: Yao, Yi, et al.
Publicado: (2019)

A systematic review of evidence for and against routine surveillance imaging after completing treatment for childhood extracranial solid tumors
por: Morgan, Jessica E., et al.
Publicado: (2020)

Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer
por: Shrestha, Bikram, et al.
Publicado: (2017)

Survival benefit of palliative gastrectomy followed by chemotherapy in stage IV gastric signet ring cell carcinoma patients: A large population‐based study
por: Shi, Tao, et al.
Publicado: (2019)

Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score
por: Langlais, Blake T., et al.
Publicado: (2021)

Race modifies survival benefit of guideline‐based treatment: Implications for reducing disparities in muscle invasive bladder cancer
por: Washington, Samuel L., et al.
Publicado: (2020)

Predicting survival in malignant pleural mesothelioma using routine clinical and laboratory characteristics
por: Gunatilake, Samal, et al.
Publicado: (2021)

Human papillomavirus self‐sampling with mRNA testing benefits routine screening
por: Auvinen, Eeva, et al.
Publicado: (2022)

Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib
por: Qin, Boyu, et al.
Publicado: (2021)

High number of PD‐1 positive intratumoural lymphocytes predicts survival benefit of cytokine‐induced killer cells for hepatocellular carcinoma patients
por: Chang, Boyang, et al.
Publicado: (2018)

Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels
por: Klamová, Hana, et al.
Publicado: (2013)

The impact of symptom screening on survival among patients with cancer across varying levels of pre‐diagnosis psychiatric care
por: Sutradhar, Rinku, et al.
Publicado: (2021)

Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity score‐matched survival analysis
por: Gao, Yang, et al.
Publicado: (2019)

The effects of hemoglobin levels and their interactions with cigarette smoking on survival in nasopharyngeal carcinoma patients
por: Zeng, Qi, et al.
Publicado: (2016)

Survival benefits of simple versus extended cholecystectomy and lymphadenectomy for patients with T1b gallbladder cancer: An analysis of the surveillance, epidemiology, and end results database (2004 to 2013)
por: Xu, Li, et al.
Publicado: (2020)

Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real‐world evidence from the medicare population
por: Goyal, Ravi K., et al.
Publicado: (2021)

Hospital‐level compliance with the commission on cancer’s quality of care measures and the association with patient survival
por: Nussbaum, Daniel P., et al.
Publicado: (2021)

Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer
por: Pruitt, Sandi L., et al.
Publicado: (2021)

Software for Administering the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study
por: Schoen, Martin W, et al.
Publicado: (2018)

Survival benefit from immunocheckpoint inhibitors in stage IV non‐small cell lung cancer patients with brain metastases: A National Cancer Database propensity‐matched analysis
por: Takamori, Shinkichi, et al.
Publicado: (2020)

Surgery shows survival benefit in patients with primary intestinal diffuse large B‐cell lymphoma: A population‐based study
por: Wang, Moran, et al.
Publicado: (2021)

Value‐based pricing: Toward achieving a balance between individual and population gains in health benefits
por: Parmar, Ambica, et al.
Publicado: (2019)

Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patients
por: Cui, Shaohua, et al.
Publicado: (2016)

The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice
por: Parikh, Sameer A., et al.
Publicado: (2020)

Association between patient‐initiated emails and overall 2‐year survival in cancer patients undergoing chemotherapy: Evidence from the real‐world setting
por: Coquet, Jean, et al.
Publicado: (2020)

Patient expectations of benefit from systemic treatments for metastatic prostate cancer
por: Oswald, Laura B., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_t6e32dh00tfl1i7c5mjp28vkup